
Opinion|Videos|August 9, 2024
Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024
Key opinion leaders (KOLs) examine real-world evidence and draw on their clinical experiences to inform their practice, discussing real-world dose escalations and key insights gained from practical application.
Advertisement
Episodes in this series

- Focusing on real-world evidence (RWE), how do outcomes compare what’s seen in practice and how does that impact your choice of therapy?
- Real-world dose escalation and outcomes of luspatercept across all LOTs (
Patel K, et al. EHA 2024. Abstract P768. )
- Real-world dose escalation and outcomes of luspatercept across all LOTs (
- IMerge study, PROs in heavily pre-treated patients with LR-MDS:
Sekeres MA, et al. Blood. 2023; 142 (suppl 1):6479. - Real World Data Replicates Medalist Study Results (
Komrokji RS et al. Blood 2022 )
- Can each of you share any key takeaways or additional data updates surrounding lower-risk MDS presented at EHA 2024? (if time permits)
- Let’s discuss novel agents and/or combination strategies in LR-MDS through ongoing research that may shape the future treatment landscape.
- Luspatercept plus erythropoietin in LR-MDS:
Jonasova A, et al. EHA 2024. Abstract P1886 . - Luspatercept plus ESA combinations in LR-MDS:
Komrokji RS, et al. Blood Adv. 2023. - Ph 2 study, elritercept (KER-050):
Díez Campelo M, et al. EHA 2024. Abstract S183 .
- Luspatercept plus erythropoietin in LR-MDS:
Advertisement
Related to this article

IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.

VGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.

EVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.

IDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.

David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.

Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.

Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.
Advertisement
Advertisement
Trending on OncLive
1
VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILs
2
EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced Melanoma
3
IDP-023 Plus Isatuximab Drives Responses in Daratumumab-Refractory Multiple Myeloma
4
Canakinumab Reduces Nodule Size in High-Risk Lung Precancers
5

